帕金森病大鼠中缝背核5-羟色胺能神经元电活动的变化

本实验采用玻璃微电极细胞外记录法,观察了帕金森病(Parkinson’s disease,PD)大鼠中缝背核(dorsal raphe nucleus, DRN)5-羟色胺(5-hydroxytryptamine,5-HT)能神经元电活动的变化。在大鼠右侧中脑黑质致密部内微量注射6-羟多巴胺(6- hydroxydopamine,6-OHDA)制作PD模型。结果显示,对照组和PD组大鼠DRN中5-HT能神经元的放电频率分别是(1．76±0．11)spikes／s(n=24)和(2．43±0．17)spikes／(n=21),PD组大鼠的放电频率显著高于对照组(P<0．001)。在对照组大鼠,92％(22／24)的神经元呈规则放电,8％(2／24)为爆发式放电;在PD组大鼠,具有规则、不规则和爆发式放电的神经元比例分别为9％(2／21)、43％(9／21)和48％(10／21),爆发式放电的5-HT能神经元比例明显高于对照组(P<0．001)。在对照组大鼠,DRN内局部注射5-HT1A拮抗剂WAY-100635(3μg/200nL)显著增加5-HT能神经元的放电频率而不影响其放电形式(n=19,P<0．002);而WAY-100635不改变PD组大鼠5-HT能神经元的放电频率和放电形式(n=17,P>0．05)。结果提示,用6-OHDA损毁黑质致密部造成的PD模型大鼠中神经元5-HT1A受体功能失调,并且DRN参与PD的病理生理学机制。     

跑台运动对攻击行为大鼠内侧下丘脑和中脑导水管周围灰质5-HT1A受体、5-HT2A受体蛋白表达的影响

目的:探讨跑台运动对攻击行为大鼠内侧下丘脑(MH)和中脑导水管周围灰质(PAG)5-HT1A受体、5-HT2A受体蛋白表达的影响,为研究运动对攻击行为改善的神经生物学机制提供实验基础.方法:3月龄雄性SD大鼠40只,体重160～180 g,随机分为4组:安静组(A)、攻击模型组(G)、攻击跑台组(GP)、入侵组(R)....     

帕金森病大鼠中缝背核5-羟色胺能神经元放电频率和放电形式的变化

实验采用玻璃微电极细胞外记录法, 观察了帕金森病(Parkinson’s disease, PD)大鼠中缝背核(dorsal raphe nucleus, DRN)5- 羟色胺(5-hydroxytrypamine, 5-HT)能神经元电活动的变化。结果发现, 对照组和 PD 组大鼠 DRN 中 5-HT 能神经元的放电频率分别为(1.61 ±0.56) Hz 和(2.61 ±1.97) Hz, PD 组大鼠的放电频率显著高于对照组(P<0.05)。在对照组大鼠, 79% 的神经元呈现规则放电, 21% 为爆发式放电;在 PD 组大鼠,具有规则、不规则和爆发式放电的神经元比例分别为 36%、16% 和47%, 爆发式放电的 5-HT 能神经元比例明显高于对照组(P<0.05)。结果表明,帕金森病大鼠 DRN 中 5-HT 能神经元的放电频率增高, 且爆发式放电增多。     

5-HT1A受体对新生大鼠离体延髓脑片呼吸节律性放电的调制

本研究探讨5-HT1A受体在延髓基本节律性呼吸放电发生和调节中的作用。以改良Kreb＇s液恒温灌流新生Sprague-Dawley大鼠离体延髓脑片标本,稳定记录与之相连的舌下神经根的呼吸节律性放电活动（respiratory rhythmical discharge activity,RRDA）后,第一组在灌流液中分别单独给予5-HT1A受体的特异性激动剂8-羟四氢萘[（＋／-）-8-hydroxy-2-（di-N-propylamino）tetralin hydrobromide,8-OHDPAT]和特异性拮抗剂多次甲基多苯基多异氰酸酯[4-iodo-N-[2-[4-methoxyphenyl]-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride,PMPPI];第二组分别先后给予8-0HDPAT和8-0HDPAT＋PMPPI,观察舌下神经根RRDA的变化,探讨5-HT1A受体对其调节作用。结果显示,给予8-OHDPAT后,呼吸周期（respiratory cycle,RC）和呼气时程（expiratory time,TE）显著延长,放电的积分幅度（integral amplitude,IA）持续降低,吸气时程（inspiratory time,TI）无明显变化;给予PMPPI后RC、TI和TE明显缩短,舌下神经根IA无明显变化,且8-OHDPAT的作用可部分被PMPPI逆转。结果提示,5-HT1A受体参与了哺乳动物基本呼吸节律的产生和调节。     

5-HT1A受体阻断剂对乙醇引起大鼠低体温和行为性体温调节反应的影响

目的：观察5-羟色胺1A （5-HT_1A）受体阻断剂p-MPPI对乙醇引起大鼠低体温和行为性体温调节反应的影响。方法：用无线遥控测温技术记录成年雄性SD大鼠体核温度和活动的变化。用无线遥测温度梯度仪监测大鼠体核温度和行为性体温调节活动,将大鼠置于15℃~40℃的温度梯度箱内,并允许动物自由选择箱内温度,观察乙醇（3 g/kg）引起低体温和行为性体温调节的反应以及5-HT_1A受体阻断剂p-MPPI （1 mg/kg）对其效应的影响。结果：①乙醇能引起大鼠快速的体温降低反应,同时动物选择较低的环境温度。②5-HT_1A受体阻断剂p-MPPI能明显阻断乙醇引起的低体温和行为性体温调节变化。结论：①乙醇能使体温调定点降低,因为乙醇引起低体温时,大鼠选择较冷环境温度区;②5-HT可能参与乙醇引起低体温与行为性体温调节活动。     

大鼠灰翼区微量注射6-羟多巴胺对迷走-迷走抑胃反射的影响

本文用乌拉坦麻醉的大鼠,观察了灰翼区微量注射6-羟多巴胺(6-OHDA)对迷走-迷走抑胃反射的影响。实验动物分三组:空白对照组、溶媒组和6-OHDA 组。实验结果表明,在溶媒组刺激迷走神经中枢端使胃电慢波的振幅和胃内压分别下降到刺激前对照值的36.87±22.07%和32.52±25.41%,与空白对照组相比无显著的差异(P>0.05)。但是,在6-OHDA组,刺激迷走神经中枢端对胃电和胃运动的抑制效应明显减弱,慢波的振幅与胃内压分别下降到刺激前对照值的67.48±13.21%和50.88±21.40%,同溶媒组相比有非常显著的差异(P<0.01)。结果提示,延髓灰翼区的儿茶酚胺能神经参与迷走-迷走抑胃反射的中枢机制。     

丁苯酞对缺血性脑卒中大鼠记忆能力及海马5-HT1A受体和PKA信号通路活化的影响

目的:研究丁苯酞对缺血性脑卒中大鼠学习和记忆能力的影响和大鼠海马5-HT1A受体和PKA信号通路的调控作用。方法:将雄性SD大鼠随机分为假手术组、模型组和丁苯酞组(n=15)。丁苯酞组大鼠建立大脑中动脉闭塞模型,并按照每天60 mg/kg的剂量灌胃丁苯酞,假手术组和模型组灌胃等体积的玉米油,共给药2周。治疗完成后对各组大鼠进行神经功能缺损评估和Morris水迷宫测试(n=15)。通过磁共振成像(MRI)检测梗塞区域(n=15)。ELISA法检测海马组织PKA激酶活性(n=6)。使用钙检测试剂盒测定海马组织的细胞内[Ca²⁺]浓度(n=6)。Western blot检测海马组织中5-羟色胺(1A)受体(5-HT1A)、谷氨酸N-甲基-D-天冬氨酸受体1(NMDA1)和α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体1(AMPA1)的表达(n=6)。结果:与模型组相比:丁苯酞组大鼠的逃避潜伏期显著降低,而穿越平台次数显著升高(P<0.05);大鼠的神经功能缺损评分和脑梗死体积较显著降低(P<0.05);大鼠的PKA激酶活性和细胞内[Ca²⁺]浓度显著升高(P<0.05);丁苯酞组大鼠的5-HT1A蛋白相对表达量显著降低,而AMPA1和NMDA1的磷酸化水平显著升高(P<0.05)。结论:丁苯酞可改善缺血性脑卒中大鼠的学习和记忆能力,下调海马5-HT1A受体活性并激活PKA信号通路。     

钩藤水提物Batch-2对6-羟多巴胺诱导的SH-SY5Y细胞损伤的神经保护作用

以前的药理学研究表明,钩藤水溶性提取物C-MED-100^TM不仅具有抗氧化活性,而且还具有很好的DNA修复和免疫功能．Batch-2是一种新的水溶性钩藤提取物,而它的自由基清除能力及神经保护作用还未见报道．首先检测了batch-2对六羟多巴胺诱导的SH-SY5Y细胞损伤的神经保护作用机制,然后利用红外光谱、HPLC和分光光度技术对batch-2的组成成分进行了分析．结果表明,batch-2具有清除各种自由基的能力,尤其是对羟自由基的清除(25 mg/L的batch-2对羟自由基的清除率为60%),batch-2可剂量依赖性地抑制6-羟多巴胺诱导的细胞凋亡、脂质过氧化水平、线粒体膜电位的降低和细胞内活性氧和一氧化氮的增加．同时,batch-2抑制了由6-羟多巴胺诱导的SH-SY5Y细胞内iNOS和NF-κB蛋白的上调．结果表明,batch-2对六羟多巴胺诱导的SH-SY5Y细胞损伤的神经保护作用是通过清除活性氧和一氧化氮、抑制iNOS和NF-κB表达实现的．成分分析表明,batch-2中的多酚和奎宁酸含量分别为6.43%和0.095 8%．上述结果显示,batch-2的抗氧化机制部分类似于EGCG．对于帕金森病的预防,batch-2是一个潜在具有很好的神经保护作用的天然抗氧化剂．     

大鼠脑实质内远位触液神经元中5-HT1A受体的分布及其在神经病理性痛中的表达

本文旨在探讨大鼠脑实质内远位触液神经元中5-HT1A受体的分布及其在神经病理性痛中的作用.慢性结扎损伤坐骨神经建立大鼠神经病理性痛模型,分别以缩足潜伏期(paw withdrawal latency,PWL)和缩足阈值(paw withdrawal threshold,PWT)对大鼠热痛敏和机械触诱发痛反应进行评分,以可靠CB-HRP(cholera toxin subunit B with horseradish peroxidase)法追踪标记脑实质内远位触液神经元,用CB-HRP/5-HT1A受体免疫组织化学双重标记技术定位、鉴别5-HT1A受体在远位触液神经元中的表达,并计数分析5-HT1A受体分布和表达变化与痛行为表现之间的关系.结果表明,在神经病理性痛第1、3、A7、14天,大鼠的PWL分别为19.37±2.74、12.04±1.77、8.74±1.15、12.31±1.94,PWT分别为18.58±3.62、13.05±1.81、6.66±1.43、1 1.55±2.01.CB-HRP标记细胞出现的位置和数量恒定.每只动物CB-HRP/5-HT1A受体双重标记的细胞数量分别为276.14±36.00、161.72±28.41、108.64±6.8l、139.76±44.64,分别占该动物CB-HRP标记细胞总数的95%、60%、40%和55%.与对照组相比,神经病理性痛大鼠PWL、PWT及CB.HRP/5-HT1A受体双标细胞数均有显著性差异(P<0.01).结果提示,大鼠脑实质的特定部位恒定存在远位触液神经元,该类神经元大多含有5-HT1A受体,该受体的表达与神经病理性痛行为表现之间呈负相关关系.     

m6A去甲基化酶ALKBH5对大鼠S1PR3基因3′-非编码区双荧光素酶活性的影响

[目的]明确m⁶A去甲基化酶ALKBH5对含S1PR3基因3′-非编码区(3′-UTR)双荧光素酶报告基因的调控作用。[方法]以大鼠前额叶皮层脑区cDNA为模板,利用聚合酶链式反应(PCR)扩增S1PR3基因3′-UTR中含有m⁶A修饰位点的目的片段。利用重叠延伸PCR方法将三个靶序列GGACT、GGACT、AGACT中的第三位A突变为C,并将野生型S1PR3-3′-UTR片段和突变型S1PR3-mut-3′-UTR片段分别正向插入到pmiR-RB-Report^TM vector载体中。将pcDNA3.1-ALKBH5或空载体pcDNA3.1与野生型和突变型双荧光素酶报告载体分别共转染PC12细胞,并检测荧光素酶活性。[结果]成功构建了包含S1PR3基因3′-UTR野生型双荧光素酶报告载体pmiR-S1PR3-3′-UTR和突变型双荧光素酶报告载体pmiR-S1PR3-mut-3′-UTR。荧光素酶活性分析表明与空载体pcDNA3.1组相比,ALKBH5可显著降低野生型及突变型C1和C2报告载体荧光素酶的活性(P<...     

WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system

We present evidence that the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl}-N-(2-pyridinyl)cyclohexanecarboxamide (WAY-100635), can induce receptor internalization in a human (h)5-HT(1A) receptor Chinese hamster ovary (CHO-K1) cell system. Exposure of h5-HT(1A) CHO cells to WAY-100635 decreased the cell-surface h5-HT(1A) receptor density in a way that was both time (24-72 h) and concentration (1-100 nm) dependent.[(3)H]WAY-100635 and [(3)H]8-hydroxy-dipropylaminotetralin ([(3)H]8-OH-DPAT) saturation analyses demonstrated a significant reduction (50-60%) in total h5-HT(1A) receptor number in the WAY-100635-treated (100 nm; 72 h) compared with control cells. In WAY-100635-treated cells, the 8-OH-DPAT-mediated inhibition of forskolin (FSK)-stimulated cAMP accumulation was right-shifted and the maximal inhibitory response of 8-OH-DPAT was impaired compared with control cells. Similar results were obtained for 8-OH-DPAT-mediated Ca(2+) mobilization after WAY-100635 treatment. h5-HT(1A) receptors labeled with [(3)H]WAY-100635, as well as [(3)H]4-(2'-Methoxy)-phenyl-1-[2'-(N-2'-pyridinyl)-p-fluorobenzamido]ethyl-piperazine (MPPF), exhibited a time-dependent rate of cellular internalization that was blocked by endocytotic suppressors and was pertussis-toxin insensitive. In contrast, quantitative autoradiographic studies demonstrated that chronic treatment of rats with WAY-100635 for two weeks produced a region-specific increase in the 5-HT(1A) receptor density. In conclusion, prolonged exposure of an h5-HT(1A) cell-based system to the 5-HT(1A) antagonist, WAY-100635, induced a paradoxical internalization of cell surface receptor resulting in depressed functional activity. This suggests that an antagonist can influence 5-HT(1A) receptor recycling in vitro differently to in vivo regulatory conditions.     

Characterisation of the Binding of [3H]WAY-100635, a Novel 5-Hydroxytryptamine1A Receptor Antagonist, to Rat Brain

Abstract: The specific binding of [³H]WAY-100635 {N-[2-[4-(2-[O-methyl-³H]methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexane carboxamide trihydrochloride} to rat hippocampal membrane preparations was time, temperature, and tissue concentration dependent. The rates of [³H]WAY-100635 association (k₊₁ = 0.069 ± 0.015 nM^?1 min^?1) and dissociation (k_?1 = 0.023 ± 0.001 min^?1) followed monoexponential kinetics. Saturation binding isotherms of [³H]WAY-100635 exhibited a single class of recognition site with an affinity of 0.37 ± 0.051 nM and a maximal binding capacity (B_max) of 312 ± 12 fmol/mg of protein. The maximal number of binding sites labelled by [³H]WAY-100635 was ～36% higher compared with that of 8-hydroxy-2-(di-n-[³H]-propylamino)tetralin ([³H]8-OH-DPAT). The binding affinity of [³H]WAY-100635 was significantly lowered by the divalent cations CaCl₂ (2.5-fold; p < 0.02) and MnCl₂ (3.6-fold; p < 0.05), with no effect on B_max. Guanyl nucleotides failed to influence the K_D and B_max parameters of [³H]WAY-100635 binding to 5-HT_1A receptors. The pharmacological binding profile of [³H]WAY-100635 was closely correlated with that of [³H]8-OH-DPAT, which is consistent with the labelling of 5-hydroxytryptamine_1A (5-HT_1A) sites in rat hippocampus. [³H]WAY-100635 competition curves with 5-HT_1A agonists and partial agonists were best resolved into high- and low-affinity binding components, whereas antagonists were best described by a one-site binding model. In the presence of 50 µM guanosine 5′-O-(3-thiotriphosphate) (GTPγS), competition curves for the antagonists remained unaltered, whereas the agonist and partial agonist curves were shifted to the right, reflecting an influence of G protein coupling on agonist versus antagonist binding to the 5-HT_1A receptor. However, a residual (16 ± 2%) high-affinity agonist binding component was still apparent in the presence of GTPγS, indicating the existence of GTP-insensitive sites.     

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

Atypical antipsychotic drugs (APDs), all of which are relatively more potent as serotonin (5-HT)(2A) than dopamine D(2) antagonists, may improve negative symptoms and cognitive dysfunction in schizophrenia, in part, via increasing cortical dopamine release. 5-HT(1A) agonism has been also suggested to contribute to the ability to increase cortical dopamine release. The present study tested the hypothesis that clozapine, olanzapine, risperidone, and perhaps other atypical APDs, increase dopamine release in rat medial prefrontal cortex (mPFC) via 5-HT(1A) receptor activation, as a result of the blockade of 5-HT(2A) and D(2) receptors. M100907 (0.1 mg/kg), a 5-HT(2A) antagonist, significantly increased the ability of both S:(-)-sulpiride (10 mg/kg), a D(2) antagonist devoid of 5-HT(1A) affinity, and R:(+)-8-OH-DPAT (0.05 mg/kg), a 5-HT(1A) agonist, to increase mPFC dopamine release. These effects of M100907 were abolished by WAY100635 (0.05 mg/kg), a 5-HT(1A) antagonist, which by itself has no effect on mPFC dopamine release. WAY100635 (0.2 mg/kg) also reversed the ability of clozapine (20 mg/kg), olanzapine (1 mg/kg), risperidone (1 mg/kg), and the R:(+)-8-OH-DPAT (0.2 mg/kg) to increase mPFC dopamine release. Clozapine is a direct acting 5-HT(1A) partial agonist, whereas olanzapine and risperidone are not. These results suggest that the atypical APDs via 5-HT(2A) and D(2) receptor blockade, regardless of intrinsic 5-HT(1A) affinity, may promote the ability of 5-HT(1A) receptor stimulation to increase mPFC DA release, and provide additional evidence that coadministration of 5-HT(2A) antagonists and typical APDs, which are D(2) antagonists, may facilitate 5-HT(1A) agonist activity.     

Tissue distribution, autoradiography, and metabolism of 4-(2'-methoxyphenyl)-1-[2' -[N-2"-pyridinyl)-p-[(18)F]fluorobenzamido]ethyl]piperazine (p-[(18)F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: An In vivo study in rats

The in vivo behavior of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p-[(18)F]fluorobenzamido ]ethyl]-piperazine (p-[(18)F]MPPF), a new serotonin 5-HT(1A) antagonist, was studied in awake, freely moving rats. Biodistribution studies showed that the carbon-fluorine bond was stable in vivo, that this compound was able to cross the blood-brain barrier, and that a general diffusion equilibrium could account for the availability of the tracer. The great quantity of highly polar metabolites found in plasma did not contribute to the small amounts of metabolites found in hippocampus, frontal cortex, and cerebellum. Exvivo p-[(18)F]MPPF and in vitro 8-hydroxy-2-(di-n-[(3)H]propylamino)tetralin autoradiography were compared both qualitatively and quantitatively. Qualitative evaluation proved that the same brain regions were labeled and that the p-[(18)F]MPPF labeling is (a) in total agreement with the known distribution of 5-HT(1A) receptors in rats and (b) characterized by very low nonspecific binding. Quantitative comparison demonstrated that the in vivo labeling pattern obtained with p-[(18)F]MPPF cannot be explained by differences in regional blood flow, capillary density, or permeability. The 5-HT(1A) specificity of p-[(18)F]MPPF and binding reversibility were confirmed in vivo with displacement experiments. Thus, this compound can be used to evaluate parameters characterizing 5-HT(1A) binding sites in the brain.     

Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

In order to determine whether L-DOPA-derived extracellular dopamine (DA) in the striatum with dopaminergic denervation is affected by activation of serotonin autoreceptors (5-HT(1A) and 5-HT(1B) receptors), we applied in vivo brain microdialysis technique to 6-hydroxydopamine-lesioned rats and examined the effects of the selective 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the selective 5-HT(1B) receptor agonist CGS-12066 A on L-DOPA-derived extracellular DA levels. Single L-DOPA injection (50 mg/kg i.p.) caused a rapid increase and a following decrease of extracellular DA, with a peak value at 100 min after L-DOPA injection. Pretreatment with both 0.3 mg/kg and 1 mg/kg 8-OH-DPAT (i.p.) significantly attenuated an increase in L-DOPA-derived extracellular DA and the times of peak DA levels were prolonged to 150 min and 225 min after L-DOPA injection, respectively. These 8-OH-DPAT-induced changes in L-DOPA-derived extracellular DA were antagonized by further pretreatment with WAY-100635, a selective 5-HT(1A) antagonist. In contrast, intrastriatal perfusion with the 5-HT(1B) agonist CGS-12066 A (10 nM and 100 nM) did not induce any changes in L-DOPA-derived extracellular DA. Thus, stimulation of 5-HT(1A) but not 5-HT(1B) receptors attenuated an increase in extracellular DA derived from exogenous L-DOPA. These results support the hypothesis that serotonergic neurons are primarily responsible for the storage and release of DA derived from exogenous L-DOPA in the absence of dopaminergic neurons.     

Regional changes in density of serotonin transporter in the brain of 5-HT1A and 5-HT1B knockout mice, and of serotonin innervation in the 5-HT1B knockout

5-HT1A knockout (KO) mice display an anxious-like phenotype, whereas 5-HT1B KOs are over-aggressive. To identify serotoninergic correlates of these altered behaviors, autoradiographic measurements of 5-HT1A and 5-HT1B serotonin (5-HT) receptors and transporter (5-HTT) were obtained using the radioligands [3H]8-OH-DPAT, [125I]cyanopindolol and [3H]citalopram, respectively. By comparison to wild-type, density of 5-HT1B receptors was unchanged throughout brain in 5-HT1A KOs, and that of 5-HT1A receptors in 5-HT1B KOs. In contrast, decreases in density of 5-HTT binding were measured in several brain regions of both genotypes. Moreover, 5-HTT binding density was significantly increased in the amygdalo-hippocampal nucleus and ventral hippocampus of the 5-HT1B KOs. Measurements of 5-HT axon length and number of axon varicosities by quantitative 5-HT immunocytochemistry revealed proportional increases in the density of 5-HT innervation in these two regions of 5-HT1B KOs, whereas none of the decreases in 5-HTT binding sites were associated with any such changes. Several conclusions could be drawn from these results: (i) 5-HT1B receptors do not adapt in 5-HT1A KOs, nor do 5-HT1A receptors in 5-HT1B KOs. (ii) 5-HTT is down-regulated in several brain regions of 5-HT1A and 5-HT1B KO mice. (iii) This down-regulation could contribute to the anxious-like phenotype of the 5-HT1A KOs, by reducing 5-HT clearance in several territories of 5-HT innervation. (iv) The 5-HT hyperinnervation in the amygdalo-hippocampal nucleus and ventral hippocampus of 5-HT1B KOs could play a role in their increased aggressiveness, and might also explain their better performance in some cognitive tests. (v) These increases in density of 5-HT innervation provide the first evidence for a negative control of 5-HT neuron growth mediated by 5-HT1B receptors.     

大鼠中央杏仁核5-HT3受体参与胸腺功能调制

本研究旨在探讨大鼠中央杏仁核(central amygdala,CeA)内5-HT3受体激动之后,对丝裂原刀豆球蛋白A(concanavalin A,ConA)刺激的胸腺细胞增殖反应的影响,及其潜在的神经内分泌调节环路.分别经大鼠腹腔(intraperitoneal,i.p.)、双侧侧脑室(intracerebroventricle,i.c.v.)和双侧CeA(intracentral amygdala,i.c.a.)注射选择性5-HT3受体激动剂1-phenylbiguanide(PBG),同时制备正常大鼠胸腺细胞悬液与不同浓度PBG(1×10-8～1×10-5 mol/L)体外共同孵育.经MTT法测定显示,无论有无ConA刺激,正常大鼠离体胸腺细胞在与PBG(1×10-8～1×10-5 mol/L)体外共同孵育时其增殖反应均不受后者影响;PBG i.p.(每天0.5 mg/kg,连续5 d)对ConA刺激的胸腺细胞的增殖反应亦无影响,而PBG i.c.v.(每天10 μg/侧,连续5 d)则显著增强之;当PBG i.c.a.(每天1.0 μg/侧,1 d或连续3、5、7 d)时,ConA刺激的胸腺细胞的增殖反应于给药后第1天即开始增强且日益显著,第5天达到高峰,第7天则趋于减弱.在给予PBG 5 min前相同给药部位先给予5-HT3受体拮抗剂tropisetvon(TRP)预处理可逆转PBG的促胸腺细胞增殖效应.免疫组织化学SABC法检测显示,PBG(1.0 μg/侧,i.c.a.)单次给药后各脑区可相继出现大量c-Fos阳性细胞(CeA1 h;海马及皮层1～2 h;下丘脑4 h;中脑导水管周围灰质8 h),并迅速达到各自高峰(CeA1 h;海马及皮层2 h;下丘脑4 h),与相应的生理盐水对照组及TRP预处理组相比均有显著性差异.随后,这一表达在各脑区中逐步减弱并消失(CeA4 h;海马、皮层及下丘脑8 h).由此推论,大鼠CeA内5-HT3受体至少可部分通过边缘系统-皮层-下丘脑-中脑导水管周围灰质这一神经内分泌环路调制胸腺细胞功能.     

5-HT_(1A)受体参与学习记忆的分子机制研究进展

5-HT(五羟色胺)能神经元是起源最早的神经元之一,在传统的神经元形成前,成长中的轴突就可释放5-HT,并且通过5-HT的各种亚型受体来实现不同的功能。近年来,随着5-HT、5-HTRs(五羟色胺受体)的基因克隆及5-HT受体选择性激动剂和拮抗剂的研究发展,5-HT系统在学习记忆中的作用越发明确,许多研究结果表明:5-HT系统在记忆的巩固、短时程记忆(STM)及长时程记忆(LTM)中起重要作用,5-HT1A受体更是在非脊椎动物及哺乳动物的脑中都高度表达,并通过相似的信号转导途径参与学习与记忆的形成和巩固。本文将介绍5-HT1A受体、5-HT1A受体激动剂、5-HT1A受体拮抗剂及其与学习记忆的联系,重点综述5-HT1A受体参与学习记忆的信号转导途径研究进展,讨论5-HT1A受体参与学习记忆的可能性分子神经生物学机制。